These kits are manufactured in accordance with the 98/79 EC directive for in vitro diagnostic devices. Only CE marked products can be used for diagnostic applications in Europe.
These kits are intended for in vitro diagnostic use.
These kits are for research use only and are not intended to be used for diagnostic procedures.
Federal Drug Administration, FDA validates diagnostic kits for in vitro diagnostic use in the United States.
Biological risk products.
Storage between 2 and 8 ° C.
Reactive in liquid form.
Reactive in lyophilized form.
Reactive in frozen form.
Stability after opening at 2-8 ° C.
Products that can be refrozen.
Stability 12 months after refreezing at -20 ° C.
The IMUCLONE ™ Total TAFI ELISA is an in vitro test for the measurement of TAFI antigen in human plasma or in any fluid containing TAFI.
Your opinion on this product ?
Number of assays
12 x 8
The Safety Data Sheets and Notices are accessible to our registered customers.
TAFI, thrombin-activatable fibrinolytic inhibitor, (also known as carboxypeptidase U and plasma pro-carboxypeptidase B) is a 60kDa molecular weight glycoprotein (proenzyme form) found in human plasma that modulates fibrinolysis. This proenzyme is converted to an active form of molecular ratio 35kDa, TAFIa, after proteolytic cleavage by the thrombin / thrombomodulin complex.
TAFIa possesses carboxypeptidase activity with a preference for cleavage of lysine and arginine residues from the end of proteins. Modulation of fibrinolysis occurs when TAFIa cleaves the C-terminal arginine and lysine residues of partially degraded fibrin. Removal of arginine and lysine residues from fibrin inhibits the continued degradation of fibrin by tPA-activated plasmin. TAFI may play a central role in thrombosis and fibrinolysis due to its ability to delay fibrin clot lysis.
The TAFI contained in the samples is captured by the capture monoclonal antibody located at the bottom of the wells. After washing, the TAFI is revealed by an anti-human TAFI polyclonal antibody coupled to peroxidase.
The TMB will thus react with the peroxidase to form a blue colored compound which will be stopped by the stop solution to give a yellow compound where the absorbance of the solution is measured at 50 nm.
Absorbance is directly proportional to the amount of TAFI present in the sample.
- 96-well microtest plate coated with human anti-TAFI antibody
- 2 vials x Sample Diluent-F, 50 mL
- 1 vial x conjugate diluent, 25 mL
- 3 vials x human anti-TAFI antibody immunoconjugate coupled to HRP, lyophilized
- 1 vial x washing solution, 20 x concentrate, 50 mL
- 1 vial x TMB substrate, ready to use, 25 mL
- 1 bottle x stop solution, 6 mL
- 3 vials x TAFI plasma calibrator, lyophilized
- 1 vial x TAFI Control I - High, lyophilized
- 1 vial x TAFI Control II - Low, lyophilized